Physician profile
Harendra Patel
NPI 1053591701
$3,590.59
in general payments reported to CMS, 2019-2025
27 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2021: $28.12 · 2022: $220 · 2023: $658 · 2024: $1,120 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,437.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $904.55 | 2019 | |
| Shockwave Medical, INC | $313.50 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $254.01 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $248.23 | 2021-2025 | |
| Abbott Laboratories | $208.01 | 2022-2024 | Cardiomems |
| Atricure, INC. | $192.56 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Esperion Therapeutics, INC. | $146.22 | 2023-2024 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $143.19 | 2024-2025 | Wainua, Farxiga |
| Novo Nordisk INC | $142.85 | 2024-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $129.30 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $120.80 | 2022-2025 | Camzyos |
| Stryker Corporation | $116.69 | 2025 | Actishield |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.24 | 2022-2024 | Lifevest |
| Kestra Medical Technology Services, INC. | $102.39 | 2024 | Assure Wcd |
| Merck Sharp & Dohme LLC | $87.27 | 2024-2025 | Verquvo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $61.14 | 2023 | Hawkone |
| Alnylam Pharmaceuticals INC. | $59.25 | 2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $57.26 | 2024 | |
| Baxter Healthcare | $33.62 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Cvrx, INC. | $24.14 | 2025 | Barostim Neo System |
| Edwards Lifesciences Corporation | $24.01 | 2023 | Sapien 3 Ultra Resilia |
| Kiniksa Pharmaceuticals International, Plc | $21.30 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $21.17 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals, Ltd. | $21.06 | 2023 | Arcalyst |
| Heartflow, INC. | $19.75 | 2022 | |
| Pfizer INC. | $13.32 | 2022 | |
| Acacia Pharma INC | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harendra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.